Business
Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th
Phio's INTASYL™ compounds demonstrated activity against multiple protein targets including PD-1, BRD4, CTLA-4, TIGIT and CTGF. INTASYL™ compounds demonstrated
About this update from Phio Pharmaceuticals Corp.
[{"type":"text","content":"Phio's INTASYL™ compounds demonstrated activity against multiple protein targets including PD-1, BRD4, CTLA-4, TIGIT and CTGF.\nINTASYL™ compounds demonstrated preclinical activity in both Direct-to-Tumor applications (PH-894, PH-109 and CTLA-4) and Adoptive Cell Therapy applications (PH-762 and PH-804).\nMARLBOROUGH, Mass., Nov. 10, 2022 /PRNewswire/ -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology makes immune cells more effective in killing tumor cells, today announced the results of several studies of its INTASYL™ compounds.\nLogo - https://mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg\nINTASYL compounds are chemically modified siRNA's that provide efficient, spontaneous cellular uptake and potent, long lasting intracellular activity targeting a broad range of cell types and tissues.\nINTASYL drugs precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. INTASYL demonstrated preclinical efficacy in both Direct-to-Tumor and Adoptive Cell Therapy (ACT) applications.\nINTASYL is the only self-delivering RNA interference (RNAi) technology focused on immuno-oncology therapeutics. Phio is developing several INTASYL compounds, one of which is in an on-going Phase 1b clinical trial for the treatment of advanced melanoma.\nThe posters will be presented on November 10th and 11th at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which is being held in Boston, MA from November 8 – 12, 2022.\nAbout the Posters\nAbstract #788 titled: A Phase 1b study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of neoadjuvant use of PH-762 administered intratumorally in subjects with advanced melanomaAbout PH-762: PH-762 is an INTASYL compound that reduces the expression of PD-1, a protein that inhibits T cells' ability to kill cancer cells. By suppressing PD-1, the T cells are re-activated to kill cancer cells. PH-762 is being developed as a standalone drug therapy (Direct-to-Tumor) and also in combination with ACT.About the poster: This trial in progress poster reports on the clinical trial design and updates on the continuing enrollment in its Phase 1b study of PH-762 for the treatment of patients w...